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Abstract
The antisense oligonucleotide Nusinersen has been recently licensed to treat spinal 
muscular atrophy (SMA). Since SMA type 3 is characterized by variable phenotype 
and milder progression, biomarkers of early treatment response are urgently needed. 
We investigated the cerebrospinal fluid (CSF) concentration of neurofilaments in 
SMA type 3 patients treated with Nusinersen as a potential biomarker of treatment 
efficacy. The concentration of phosphorylated neurofilaments heavy chain (pNfH) 
and light chain (NfL) in the CSF of SMA type 3 patients was evaluated before and 
after six months since the first Nusinersen administration, performed with commer-
cially available enzyme-linked immunosorbent assay (ELISA) kits. Clinical evaluation 
of SMA patients was performed with standardized motor function scales. Baseline 
neurofilament levels in patients were comparable to controls, but significantly de-
creased after six months of treatment, while motor functions were only marginally 
ameliorated. No significant correlation was observed between the change in motor 
functions and that of neurofilaments over time. The reduction of neurofilament lev-
els suggests a possible early biochemical effect of treatment on axonal degeneration, 
which may precede changes in motor performance. Our study mandates further in-
vestigations to assess neurofilaments as a marker of treatment response.
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1  | INTRODUC TION
Spinal muscular atrophy (SMA) is an autosomal recessive neuromus-
cular disease caused by mutations in the Survival Motor Neuron 1 
(SMN1) gene. The most severe form of this disease, SMA type 1, 
becomes evident in the firsts months of life and is currently the most 
common genetic cause of death in infancy.1 On the other hand, indi-
viduals affected by SMA type 3 usually display a milder phenotype 
and a more indolent disease progression; despite this, most patients 
lose their ability to walk independently in adulthood.2 The main de-
terminant of these different outcome relates to the variable copy 
number of the gene SMN23: Most of the SMN protein that derives 
from this paralogous gene is rapidly degraded, but up to 10% of the 
total protein product is functional and may in part compensate the 
complete lack of SMN1. However, other factors are likely to play a 
role in determining the clinical phenotype.4
Nusinersen, the first marketed disease-modifying drug for 
SMA,5 is an antisense oligonucleotide that binds to the SMN2 pre-
mRNA downstream of exon 7, leading to the translation of a fully 
functional SMN protein. Nusinersen is administered intrathecally 
by lumbar puncture and has been recently licensed in Europe to 
treat SMA in each country with specific indications for the differ-
ent types of SMA.6 Results of clinical trials have shown a dramatic 
clinical and laboratory response after Nusinersen administration in 
SMA type 1 patients,7 while recent studies on late-onset SMA type 3 
provided less striking, albeit encouraging results.8 Indeed, SMA type 
3 patients display a highly variable phenotypic spectrum of disease 
and, due to the relatively milder progression typical of this subset of 
patients, clinical differences may theoretically become evident only 
after prolonged treatment. Considering the scant data available on 
Nusinersen efficacy in this population and the high cost of this in-
trathecally administered drug, robust biomarkers of early treatment 
response are required to identify patients who could benefit from 
treatment.
Phosphorylated neurofilament heavy chain (pNfH) and neu-
rofilament light chain (NfL) have been reproducibly associated 
with axonal degeneration,9 and levels of these biomarkers tend 
to increase in both cerebrospinal fluid (CSF) and plasma/serum 
of patients affected by motor neuron diseases (MNDs). As a re-
sult, neurofilaments have been increasingly recognized as a useful 
biomarker for the diagnosis of amyotrophic lateral sclerosis, and 
their concentration in the CSF is affected by disease duration, 
rate of progression and involvement of first- and second-motor 
neurons.10
A recent study suggested that plasma pNfH could be exploited as 
a biomarker of treatment response to Nusinersen in SMA type 1 pa-
tients7: increased pNfH levels at baseline with respect to 34 controls 
showed a rapid and substantial decline after only two months from 
treatment start, reaching a 90.1% relative change at 10 months. In 
the present study, we aimed to assess the levels and changes over 
time of pNfH and NfL in the CSF of type 3 SMA patients treated with 
intrathecal Nusinersen, to explore their use as a potential biomark-
ers of treatment response.
2  | MATERIAL S AND METHODS
2.1 | Clinical evaluation
Spinal muscular atrophy type 3 patients were recruited at the 
Neurology Unit of Fondazione IRCCS Ca’ Granda Ospedale 
Maggiore Policlinico di Milano and at the Neurology Unit of Azienda 
Ospedaliero-Universitaria of Pisa. Patients were evaluated with a 
6-month follow-up, starting before the first Nusinersen administra-
tion and on the following treatment days (at 2 weeks and at one, 
2 and 6 months from the first treatment, according to the national 
Agenzia Italiana del Farmaco—AIFA guidelines). All adult and pae-
diatric patients were regularly evaluated over time with standard-
ized motor function scales: Hammersmith Functional Motor Scale 
Expanded (HFMSE) and 6 Minute Walking Test (6MWT) for ambu-
lant patients. For reference, a single SMA type 1 patient undergoing 
the same procedures and evaluations was recruited from one of the 
two institutions.
The study was conducted in accordance with the Declaration of 
Helsinki and followed ICH GCP guidelines. All subjects and the par-
ents of minors provided written informed consent for the collection, 
storage and analysis of biological materials according to the disposi-
tion of the local ethics committees.
2.2 | CSF analysis
Cerebrospinal fluid samples were collected right before the in-
trathecal administration of Nusinersen. Analyses were performed 
on samples obtained on the first (pre-treatment) and on the last 
administration (6 months). CSF analyses were also performed on 
selected samples from subjects who underwent lumbar puncture 
during a diagnostic procedure for unconfirmed clinical suspicions 
and who were ultimately diagnosed with psychosomatic diseases. 
Patients with different neurological conditions (excluding neurode-
generative/motor neuron disorders) with an age range comparable 
to SMA patients were also included. CSF pNfH and NfL levels were 
measured performed with commercially available enzyme-linked 
immunosorbent assay (ELISA) kits (pNfH: Euroimmun, Lubeck, 
Germany—NfL: UmanDiagnostics AB, Umea, Sweden) according to 
the manufactures’ instructions.
2.3 | Statistical analysis
Baseline characteristics were analysed through descriptive statistics, 
continuous variables were reported as mean ± SD or median [IQR], 
as appropriate. Categorical variables were represented as numbers 
and percentages. Normality of distributions was visually inspected by 
box-plot representation and formally assessed with the D'Agostino-
Pearson's test. For both pNfH and NfL, values below the lower limit 
of quantification were approximated to half of the concentration of 
the lowest calibrator (50 pg/mL and 0.0625 ng/mL for NfL and NfH, 
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respectively). Between-group comparisons were performed with the 
Mann-Whitney test. Within-group comparisons over time were carried 
out by means of paired t test or Wilcoxon matched-pairs signed-rank 
test, as appropriate. Associations between variables were assessed 
with the nonparametric Spearman's correlation coefficient. Statistically 
significant differences were assumed at 5% level of probability, and all 
statistical tests were two-tailed. All analyses were performed with 
GraphPad Prism version 8 (GraphPad Software Inc).
3  | RESULTS
3.1 | Clinical assessment
A total of 12 patients diagnosed with SMA type 3 were enrolled in 
the study. The age of first treatment ranged from a minimum of nine 
to a maximum of 74 years, with nine patients (75%) >18 years old. 
The minimum disease duration at the start of treatment is 7.5 years, 
while the maximum duration is 32 years. Baseline characteristics are 
summarized in Table 1. Two patients used wheelchairs since the age 
of 18 and 29 years, and another two had mild respiratory involve-
ment due to restrictive pulmonary disease and obstructive sleep-ap-
noea syndrome respectively. Ten patients were ambulant, but one of 
them needed support and was able to walk only for few steps, while 
another one underwent minor orthopaedic surgery at the beginning 
of the observation period, thus only eight patients were able to per-
form the 6WMT both at baseline and at the end of the follow-up. A 
single patient with SMA type 1, who started therapy at the age of 
3 months, was also included as reference. All Nusinersen administra-
tions were well-tolerated, and the only adverse event reported was 
headache after lumbar puncture in 6 (50%) subjects after the first 
drug infusion.
Motor functions were not significantly modified by Nusinersen 
in SMA type 3 patients during the 6-month follow-up, with a 
non-significant trend towards improved performances in the 6-min-
utes walking test (+4.0 ± 17.7 metres, P = .54) and in the HFMSE score 
(+1.0 ± 3.8 points, P = .38) compared to baseline (Figure 1A and 1, 
respectively).
3.2 | Neurofilaments in the CSF
pNfH and NfL levels dosed at baseline in the CFS of SMA type 3 patients 
were comparable to those observed in controls (n = 9, age: 29.0 [22.0-
54.5] year-old) and were far below the average values described in pa-
tients affected by either SMA type 1 (6.874 ng/mL and >10 000 pg/
mL, respectively) or amyotrophic lateral sclerosis (5.270 ng/mL and 
2961 pg/mL11) (Figure 2A and 2). The baseline concentration of neu-
rofilaments in our study was below the lower limit of quantification in 
a significant proportion of patients (4/12 and 2/12 for pNfH and NfL 
respectively). In these cases, lower limit of quantification was approxi-
mated to half of the concentration of the lowest calibrator (50 pg/mL 
and 0.0625 ng/mL for NfL and NfH, respectively).
No significant correlation was observed between pNfH and ei-
ther age at treatment or duration of the disease (Figure 2B and 2). On 
the other hand, a positive correlation was found between NfL and 
age at treatment (r = 0.59, P = .046) along with a marginally signifi-
cant correlation between NfL and duration of the disease (r = 0.55, 
P = .066) (Figure 2E and 2).
Interestingly, the comparison between the values of both 
neurofilament types before and after 6 months from treatment 
start showed a slight but significant decrease (pNfH: median of 
differences −0.0236 ng/mL, P = .016—NfL: mean of differences 
−70.0 ± 97.7 pg/mL, P = .031) (Figure 3A and 3). However, no sig-
nificant correlation was observed between the pre-post–differ-
ence in HFMSE scores and the change of either pNfH or NfL over 
time (Figure 3B and 3).
Baseline values of both pNfH and NfL in the patient with SMA type 
1 were much higher than those observed in healthy controls (6.874 ng/
mL and >10 000 pg/mL, respectively), in accordance with existing data TA B L E  1   Baseline clinic characteristics of SMA type 3 patients
Characteristic SMA III (n = 12)
Female Sex – n° (%) 4 (33.3%)
Age at Onset – years 5.5 [2.3-14.8]
Age at Treatment – years 28.5 [15.0-34.8]
Disease Duration – years 20.1 ± 10.0




Ambulant – n° (%) 10 (83.3%)
Respiratory involvement – n° (%) 2 (16.7%)
HFMSE (score) 40.8 ± 13.5
6MWT (metres) 304 ± 126
Note: Categorical data expressed as number (%), continuous data 
reported as mean ± SD or median [IQR], as appropriate.
F I G U R E  1   Evaluation of standardized motor scales in SMA type 
3 patients. Individual scores at the 6 min walking test (A) and at 
the Hammersmith Functional Motor Scale Expanded (B) at baseline 
(pre) and after five injections (post) of Nusinersen
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from the literature.7,12 Levels of both neurofilament types showed a 
progressive and rapid reduction, and at 6 months from treatment start 
they were comparable to those of healthy individuals (data not shown).
4  | DISCUSSION
In this explorative study on a small cohort of SMA type 3 patients, 
we report our preliminary findings on the effects of Nusinersen ad-
ministration on motor function over the short-term and describe 
changes over time in the CSF concentration of both pNfH and NfL, 
which were assessed as potential biomarkers of treatment response.
At 6 months from treatment start, we observed a slight improve-
ment in motor functions of treated patients, which, however, did 
not reach nominal significance compared to pre-treatment values. A 
recent post hoc analysis of data from the CS2/CS12 study, which in-
cluded a subset of ambulant patients with SMA type 2 and 3 treated 
with Nusinersen, showed an improvement in motor performance 
(measured by the 6MWT) at 35 months from treatment start.13 The 
apparent inconsistence with our results is probably due to the sig-
nificantly different follow-up extension, to baseline patient charac-
teristics and disease duration. In our study, we selectively recruited 
SMA type 3 patients, who were older compared to the CS2/CS12 
cohort (64% of patients included in the study by Montes et al were 
11 years old or less). None of our patients was treated in the initial 
stages of the disease, and disease progression was slow for all of 
them. Milder phenotype and older age could explain the less striking 
effect of Nusinersen over the short follow-up of our study.
Neurofilaments in the CSF of affected patients at baseline were 
comparable to age-matched controls and were all consistently below 
the threshold values that usually define pathological samples.14 This 
finding possibly reflects the slow disease progression typical of SMA 
type 3, in which axonal degeneration is a smouldering process that 
F I G U R E  2   Cerebrospinal fluid (CSF) 
concentrations of phosphorylated 
neurofilament heavy chain (pNfH) and 
neurofilament light chain (NfL). Levels of 
pNfH (A) and NfL (D) in the CSF of SMA 
type 3 patients (SMA-3) and controls 
(median [IQR]). Correlation between pNfH 
levels and either age at treatment (B) or 
duration of disease (C). The same analyses 
for NfL are also displayed (E-F). 4 of 12 
pNfH (A) and 2 of 12 NfL (D) values at 
baseline were below the detection limit
F I G U R E  3   Cerebrospinal fluid (CSF) concentrations 
of phosphorylated neurofilament heavy chain (pNfH) and 
neurofilament light chain (NfL) at baseline and after treatment 
with Nusinersen. Individual CSF pNFH levels (A) and NfL levels (C) 
of SMA type 3 patients at baseline (Pre) and after five injections 
(Post) of Nusinersen (6-month follow-up) (n = 12); four patients had 
undetectable pNfH levels both at baseline and during follow-up, 
while two patients displayed a similar baseline value of NfL (201.1 
and 202.7 pg/mL) that became undetectable in both cases at the 
end of the follow-up. Correlation between the change in pNfH (B) 
or NfL (D) values and variations in HFMSE scores over time (n = 12); 
two patients displayed identical differences in HFMSE scores (4 
points) and differences in pNfH levels (0 ng/mL)
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is less likely to significantly affect neurofilament concentration. As 
previously described for healthy individuals,15 NfL concentration 
was positively correlated with age and duration of the disease in 
SMA type 3 patients, while pNfH levels were less influenced by pa-
tient age and disease duration.
Near-normal baseline values notwithstanding, the CSF concen-
tration of both pNfH and NfL was significantly reduced at 6 months 
compared with pre-treatment values. This finding might suggest an 
early biochemical effect of treatment, possibly reflecting decreased 
axonal degeneration, which may be captured well before any change 
in motor performance becomes clinically evident.
Similarly to our study, Wurster and colleagues16 have elegantly 
described the changes of CSF parameters over time in a cohort of 
SMA type 2 and 3 patients treated with Nusinersen. In their report, 
however, no significant difference in neurofilament concentrations 
was found between pre- and post-treatment samples. Our study de-
sign may have granted us more power to detect significant changes 
owing to its longer follow-up (6 months compared with 2 months after 
treatment start) and to the cohort restricted to SMA type 3 patients. 
In addition, patients enrolled in our study had an overall shorter dis-
ease duration, which may have further affected results. Notably, some 
of the variability in results could be potentially related to difference 
in sensitivity among ELISA kits employed, especially for pNfH levels.
Despite these encouraging results, we did not observe any signif-
icant correlation between neurofilament concentration over time and 
the change in motor functions at six months as assessed by the HFMSE 
score. We speculate that the lack of a significant clinical effect during 
this relatively short follow-up may in part explain this inconsistency.
Indeed, important limitations of our study include the small 
number of patients and the relatively short duration of follow-up. 
In addition, analytical limitations need to be discussed: the baseline 
concentration of neurofilaments in our study was below the lower 
limit of quantification in a significant proportion of patients (4/12 
and 2/12 for pNfH and NfL, respectively), thus hindering data in-
terpretation. However, the remarkable consistency of measurable 
data and the significant differences observed despite such limita-
tion, infers against a casual effect. These concerns may be addressed 
in future by the use of more sensitive methods designed to detect 
lower analyte concentrations, such as the single-molecule array im-
munoassay that has been recently developed for NfL detection.17
Overall, our studies suggest that both pNfH and NfL are reduced 
by Nusinersen administration in a significant proportion of SMA 
type 3 patients as early as six months after the first treatment, and 
mandate further investigation on the accuracy of neurofilaments as 
markers of treatment response.
ACKNOWLEDG EMENT
We gratefully thank the Associazione Centro Dino Ferrari for its 
support.
CONFLIC TS OF INTERE S T
The authors confirm that there are no conflicts of interest.
AUTHOR CONTRIBUTIONS
AG, SC, FM, IF, GR, MM, EA, DV, GC and EP visited the patients, 
performed CSF collection and drug dispensation. DS, DR, VP and 
LP performed laboratory assessment. IF and AG analysed the data 
and wrote the manuscript. All authors read and approved the final 
version of the manuscript.
DATA AVAIL ABILIT Y S TATEMENT
The data that support the findings of this study are available from 
the corresponding author upon reasonable request.
ORCID
Elena Abati  https://orcid.org/0000-0003-0797-8282 
Stefania Corti  https://orcid.org/0000-0001-5425-969X 
Francesca Magri  https://orcid.org/0000-0001-8974-9453 
Alessandra Govoni  https://orcid.org/0000-0002-5393-5462 
R E FE R E N C E S
 1. Wang CH, Finkel RS, Bertini ES, et al. Consensus statement 
for standard of care in spinal muscular atrophy. J Child Neurol. 
2007;22:1027-1049.
 2. D’Amico A, Mercuri E, Tiziano FD, Bertini E. Spinal muscular atro-
phy. Orphanet J Rare Dis. 2011;6:71.
 3. Calucho M, Bernal S, Alías L, et al. Correlation between SMA 
type and SMN2 copy number revisited: An analysis of 625 unre-
lated Spanish patients and a compilation of 2834 reported cases. 
Neuromuscul Disord NMD. 2018;28:208-215.
 4. Wirth B, Garbes L, Riessland M. How genetic modifiers influence 
the phenotype of spinal muscular atrophy and suggest future ther-
apeutic approaches. Curr Opin Genet Dev. 2013;23:330-338.
 5. Finkel RS, Mercuri E, Darras BT, et al. Nusinersen versus Sham 
Control in Infantile-Onset Spinal Muscular Atrophy. N Engl J Med. 
2017;377:1723-1732.
 6. Goodkey K, Aslesh T, Maruyama R, Yokota T. Nusinersen in the 
treatment of spinal muscular atrophy. Methods Mol Biol Clifton NJ. 
2018;1828:69-76.
 7. Darras BT, Crawford TO, Finkel RS, et al. Neurofilament as a poten-
tial biomarker for spinal muscular atrophy. Ann Clin Transl Neurol. 
2019;6:932-944.
 8. Darras BT, Chiriboga CA, Iannaccone ST, et al. Nusinersen in lat-
er-onset spinal muscular atrophy: Long-term results from the phase 
1/2 studies. Neurology. 2019;92:e2492-e2506.
 9. Perrone Capano C, Pernas-Alonso R, di Porzio U. Neurofilament ho-
meostasis and motoneurone degeneration. BioEssays News Rev Mol 
Cell Dev Biol. 2001;23:24-33.
 10. Poesen K, Van Damme P. Diagnostic and prognostic performance of 
neurofilaments in ALS. Front Neurol. 2018;9:1167.
 11. Feneberg E, Oeckl P, Steinacker P, et al. Multicenter evaluation of 
neurofilaments in early symptom onset amyotrophic lateral sclero-
sis. Neurology. 2018;90:e22-e30.
 12. Olsson B, Alberg L, Cullen NC, et al. NFL is a marker of treatment 
response in children with SMA treated with nusinersen. J Neurol. 
2019;266(9):2129-2136.
 13. Montes J, Dunaway Young S, Mazzone ES, et al. Nusinersen im-
proves walking distance and reduces fatigue in later-onset spinal 
muscular atrophy. Muscle Nerve. 2019;60(4):409-414.
 14. Khalil M, Teunissen CE, Otto M, et al. Neurofilaments as biomarkers 
in neurological disorders. Nat Rev Neurol. 2018;14:577-589.
 15. Vågberg M, Norgren N, Dring A, et al. Levels and age dependency 
of neurofilament light and glial fibrillary acidic protein in healthy 
     |  3039FARAVELLI Et AL.
individuals and their relation to the brain parenchymal fraction. 
PLoS ONE. 2015;10:e0135886.
 16. Wurster CD, Günther R, Steinacker P, et al. Neurochemical markers 
in CSF of adolescent and adult SMA patients undergoing nusinersen 
treatment. Ther Adv Neurol Disord. 2019;12:1756286419846058.
 17. Kuhle J, Barro C, Andreasson U, et al. Comparison of three ana-
lytical platforms for quantification of the neurofilament light chain 
in blood samples: ELISA, electrochemiluminescence immunoassay 
and Simoa. Clin Chem Lab Med. 2016;54:1655-1661.
How to cite this article: Faravelli I, Meneri M, Saccomanno D, 
et al. Nusinersen treatment and cerebrospinal fluid 
neurofilaments: An explorative study on Spinal Muscular 
Atrophy type 3 patients. J Cell Mol Med. 2020;24:3034–3039.  
https ://doi.org/10.1111/jcmm.14939 
